Cargando…
Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy
BACKGROUND/AIMS: This retrospective study evaluated the transplantation outcomes of patients with adult lymphoid malignancies who received chemotherapy-based conditioning with busulfan and fludarabine (BuFlu) and busulfan and cyclophosphamide (BuCy2). METHODS: Thirty-eight patients (34 with acute ly...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295992/ https://www.ncbi.nlm.nih.gov/pubmed/22403503 http://dx.doi.org/10.3904/kjim.2012.27.1.72 |
_version_ | 1782225658398638080 |
---|---|
author | Shin, Ho Cheol Lee, Yoo Jin Joon Ho, Joon Ho Lee, Soo Jung Kang, Byung Woog Chae, Yee Soo Kim, Jong Gwang Choi, Jun Young Seo, Jong Won Kim, Yu Kyung Suh, Jang Soo Sohn, Sang Kyun |
author_facet | Shin, Ho Cheol Lee, Yoo Jin Joon Ho, Joon Ho Lee, Soo Jung Kang, Byung Woog Chae, Yee Soo Kim, Jong Gwang Choi, Jun Young Seo, Jong Won Kim, Yu Kyung Suh, Jang Soo Sohn, Sang Kyun |
author_sort | Shin, Ho Cheol |
collection | PubMed |
description | BACKGROUND/AIMS: This retrospective study evaluated the transplantation outcomes of patients with adult lymphoid malignancies who received chemotherapy-based conditioning with busulfan and fludarabine (BuFlu) and busulfan and cyclophosphamide (BuCy2). METHODS: Thirty-eight patients (34 with acute lymphoblastic leukemia and 4 with lymphoblastic lymphoma) were included in the current study. The conditioning regimen was BuCy2 for 14 patients and BuFlu for the remaining 24 patients. Eight and 13 patients were high risk disease in the BuCy2 and BuFlu groups, respectively. RESULTS: The cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) was 56.5% and 55.2% and that of extensive chronic GVHD 17.0% and 55.6% (p = 0.018) for the BuFlu and BuCy2 groups, respectively. The 3-year relapse rate was 27.8% and 31.4% and 3-year overall survival 34.3% and 46.8% for the BuFlu and BuCy2 groups, respectively. Treatment-related mortality (TRM) was significantly lower in the BuFlu group (16.9%) than in the BuCy2 group (57.1%, p = 0.010). In multivariate analyses, the BuFlu regimen was identified as an independent favorable risk factor for TRM (hazard ratio [HR], 0.036; p = 0.017) and extensive chronic GVHD (HR, 0.168; p = 0.034). CONCLUSIONS: Our BuFlu regimen would appear to be an acceptable conditioning option for lymphoid malignancies, including high-risk diseases. It was safely administered with a lower TRM rate than BuCy2 conditioning. |
format | Online Article Text |
id | pubmed-3295992 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | The Korean Association of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-32959922012-03-08 Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy Shin, Ho Cheol Lee, Yoo Jin Joon Ho, Joon Ho Lee, Soo Jung Kang, Byung Woog Chae, Yee Soo Kim, Jong Gwang Choi, Jun Young Seo, Jong Won Kim, Yu Kyung Suh, Jang Soo Sohn, Sang Kyun Korean J Intern Med Original Article BACKGROUND/AIMS: This retrospective study evaluated the transplantation outcomes of patients with adult lymphoid malignancies who received chemotherapy-based conditioning with busulfan and fludarabine (BuFlu) and busulfan and cyclophosphamide (BuCy2). METHODS: Thirty-eight patients (34 with acute lymphoblastic leukemia and 4 with lymphoblastic lymphoma) were included in the current study. The conditioning regimen was BuCy2 for 14 patients and BuFlu for the remaining 24 patients. Eight and 13 patients were high risk disease in the BuCy2 and BuFlu groups, respectively. RESULTS: The cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) was 56.5% and 55.2% and that of extensive chronic GVHD 17.0% and 55.6% (p = 0.018) for the BuFlu and BuCy2 groups, respectively. The 3-year relapse rate was 27.8% and 31.4% and 3-year overall survival 34.3% and 46.8% for the BuFlu and BuCy2 groups, respectively. Treatment-related mortality (TRM) was significantly lower in the BuFlu group (16.9%) than in the BuCy2 group (57.1%, p = 0.010). In multivariate analyses, the BuFlu regimen was identified as an independent favorable risk factor for TRM (hazard ratio [HR], 0.036; p = 0.017) and extensive chronic GVHD (HR, 0.168; p = 0.034). CONCLUSIONS: Our BuFlu regimen would appear to be an acceptable conditioning option for lymphoid malignancies, including high-risk diseases. It was safely administered with a lower TRM rate than BuCy2 conditioning. The Korean Association of Internal Medicine 2012-03 2012-02-28 /pmc/articles/PMC3295992/ /pubmed/22403503 http://dx.doi.org/10.3904/kjim.2012.27.1.72 Text en Copyright © 2012 The Korean Association of Internal Medicine http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Shin, Ho Cheol Lee, Yoo Jin Joon Ho, Joon Ho Lee, Soo Jung Kang, Byung Woog Chae, Yee Soo Kim, Jong Gwang Choi, Jun Young Seo, Jong Won Kim, Yu Kyung Suh, Jang Soo Sohn, Sang Kyun Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy |
title | Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy |
title_full | Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy |
title_fullStr | Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy |
title_full_unstemmed | Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy |
title_short | Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy |
title_sort | feasibility of non-tbi conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295992/ https://www.ncbi.nlm.nih.gov/pubmed/22403503 http://dx.doi.org/10.3904/kjim.2012.27.1.72 |
work_keys_str_mv | AT shinhocheol feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy AT leeyoojin feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy AT joonhojoonho feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy AT leesoojung feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy AT kangbyungwoog feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy AT chaeyeesoo feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy AT kimjonggwang feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy AT choijunyoung feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy AT seojongwon feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy AT kimyukyung feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy AT suhjangsoo feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy AT sohnsangkyun feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy |